Print

Acorda Therapeutics (ACOR) to Present New Research on AMPYRA┬« (dalfampridine-ER) at 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)  
10/2/2013 6:29:58 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new research at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis.

Help employers find you! Check out all the jobs and post your resume.

//-->